16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients
- Type of Study
- Rheumatology - Ankylosing Spondylitis
- Short Description
The purpose of this study is to generate 16-week efficacy data, as well as up to 3-year efficacy, safety and tolerability data in subjects with active AS despite current or previous NSAID, DMARD and/or anti-TNF therapy.
- Principal Investigator
- Philip J. Mease, MD
- Eligibility Notes
Inclusion criteria: moderate to severe AS, prior radiographic evidence according to the Modified NY Criteria (1984), inadequate response to NSAIDs.
Exclusion criteria: pregnancy or lactation, on-going infectious or malignant process on a chest X-ray or MRI, previous exposure to IL-17 or IL-17R targeting therapies, previous exposure to any biological immunomodulating agent excluding TNF antagonists, previous cell depleting therapy. -- Other protocol-defined inclusion/exclusion criteria do apply.
- Start Date
- Contact Name
- Jodie Davila, RN
- Alternate Phone
- Alternate Email